AIM: Cytomegalovirus (CMV) infection is one of the most common complications in patients submitted to hematopoietic stem cell transplant (HSCT). Pre-emptive therapy has been indicated in patients with laboratory evidence of CMV replication. The aims of this study were to compare real-time PCR or pp65 antigen assay methodologies to detect CMV replication in HSCT patients, define a viral load threshold for initiation of pre-emptive therapy, and assess the feasibility of its implementation in hospitals of countries with low and middle income. MATERIAL AND METHODS: Human CMV detection by real-time PCR and pp65 antigen assay was carried out in blood and plasma samples of HSCT patients collected weekly during 3 months. Pre-emptive therapy was based on CMV antigenemia results. RESULTS: Twenty-one patients were monitored with a total of 227 samples collected; 13 (62%) patients were children. A poor correlation was observed between qualitative results, though quantitative results showed statistically significant difference, with higher viral loads detected in patients with positive antigenemia. Compared to a positive antigenemia, a cutoff value of 1067·5 copies/ml, 3·03 log10/ml, for viral load was obtained with 100% sensitivity and 71% specificity. CONCLUSION: CMV real-time PCR in whole blood was suitable for monitoring HSCT patients. However, its high cost is a limiting factor, and it could be used to monitor selected patients, those with prolonged leukopenia and underweight children, and subsequently switched to pp65 antigen test. Further studies involving larger numbers of patients should be performed to confirm this statement.
AIM: Cytomegalovirus (CMV) infection is one of the most common complications in patients submitted to hematopoietic stem cell transplant (HSCT). Pre-emptive therapy has been indicated in patients with laboratory evidence of CMV replication. The aims of this study were to compare real-time PCR or pp65 antigen assay methodologies to detect CMV replication in HSCT patients, define a viral load threshold for initiation of pre-emptive therapy, and assess the feasibility of its implementation in hospitals of countries with low and middle income. MATERIAL AND METHODS:Human CMV detection by real-time PCR and pp65 antigen assay was carried out in blood and plasma samples of HSCT patients collected weekly during 3 months. Pre-emptive therapy was based on CMV antigenemia results. RESULTS: Twenty-one patients were monitored with a total of 227 samples collected; 13 (62%) patients were children. A poor correlation was observed between qualitative results, though quantitative results showed statistically significant difference, with higher viral loads detected in patients with positive antigenemia. Compared to a positive antigenemia, a cutoff value of 1067·5 copies/ml, 3·03 log10/ml, for viral load was obtained with 100% sensitivity and 71% specificity. CONCLUSION: CMV real-time PCR in whole blood was suitable for monitoring HSCT patients. However, its high cost is a limiting factor, and it could be used to monitor selected patients, those with prolonged leukopenia and underweight children, and subsequently switched to pp65 antigen test. Further studies involving larger numbers of patients should be performed to confirm this statement.
Authors: Roland R Regoes; E Frances Bowen; Alethea V Cope; Dehila Gor; Aycan F Hassan-Walker; H Grant Prentice; Margaret A Johnson; Paul Sweny; Andrew K Burroughs; Paul D Griffiths; Sebastian Bonhoeffer; Vincent C Emery Journal: Proc Biol Sci Date: 2006-08-07 Impact factor: 5.349
Authors: Renata M B Peres; Cláudia R C Costa; Paula D Andrade; Sandra H A Bonon; Dulcinéia M Albuquerque; Cristiane de Oliveira; Afonso C Vigorito; Francisco J P Aranha; Cármino A de Souza; Sandra C B Costa Journal: BMC Infect Dis Date: 2010-06-01 Impact factor: 3.090
Authors: Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Hans H Hirsch; Irmeli Lautenschlager; Benjamin A Pinsky; Laura Cardeñoso; Shagufta Aslam; Bryan Cobb; Regis A Vilchez; Alexandra Valsamakis Journal: Clin Infect Dis Date: 2012-10-24 Impact factor: 9.079
Authors: Sandra Rosskopf; Judith Leitner; Wolfgang Paster; Laura T Morton; Renate S Hagedoorn; Peter Steinberger; Mirjam H M Heemskerk Journal: Oncotarget Date: 2018-04-03
Authors: Cornelius Engelmann; Martina Sterneck; Karl Heinz Weiss; Silke Templin; Steffen Zopf; Gerald Denk; Dennis Eurich; Johann Pratschke; Johannes Weiss; Felix Braun; Martin-Walter Welker; Tim Zimmermann; Petra Knipper; Dirk Nierhoff; Thomas Lorf; Elmar Jäckel; Hans-Michael Hau; Tung Yu Tsui; Aristoteles Perrakis; Hans-Jürgen Schlitt; Kerstin Herzer; Frank Tacke Journal: J Clin Med Date: 2020-07-23 Impact factor: 4.241
Authors: Patricia Pichilingue-Reto; Prithvi Raj; Quan-Zhen Li; Igor Dozmorov; David R Karp; Edward K Wakeland; Morgan Nelson; Rebecca S Gruchalla; M Teresa de la Morena; Nicolai S C van Oers Journal: J Clin Immunol Date: 2021-03-03 Impact factor: 8.317